Dissection of immune gene networks in primary melanoma tumors critical for antitumor surveillance of patients with stage II-III resectable disease

Journal of Investigative Dermatology

Volumn 134, Issue 8, 2014, Pages 2202-2211

  Sivendran, Shanthi ^a,b   Chang, Rui ^a   Pham, Lisa ^a   Phelps, Robert G ^a   Harcharik, Sara T ^a   Hall, Lawrence D ^c   Bernardo, Sebastian G ^a   Moskalenko, Marina M ^a   Sivendran, Meera ^c   Fu, Yichun ^a   De Moll, Ellen H ^a   Pan, Michael ^a   Moon, Jee Young ^a   Arora, Sonali ^a   Cohain, Ariella ^a   Difeo, Analisa ^d   Ferringer, Tammie C ^c   Tismenetsky, Mikhail ^a,e   Tsui, Cindy L ^a   Friedlander, Philip A ^a   Parides, Michael K ^a   Banchereau, Jacques ^a   Chaussabel, Damien ^f   Lebwohl, Mark G ^a   Wolchok, Jedd D ^g   Bhardwaj, Nina ^a,h   Burakoff, Steven J ^a   Oh, William K ^a   Palucka, Karolina ^a,i   Merad, Miriam ^a   Schadt, Eric E ^a   Saenger, Yvonne M ^a   more..

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b Lancaster General Health   (United States)

^c GEISINGER HEALTH SYSTEM   (United States)

^d CASE WESTERN RESERVE UNIVERSITY   (United States)

^e ENGLEWOOD HOSPITAL AND MEDICAL CENTER   (United States)

^f BENAROYA RESEARCH INSTITUTE   (United States)

^g MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^h NEW YORK UNIVERSITY   (United States)

ⁱ BAYLOR INSTITUTE FOR IMMUNOLOGY RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B CELL ACTIVATING FACTOR; CD2 ANTIGEN; CD27 ANTIGEN; CD37 ANTIGEN; CD4 ANTIGEN; CD40 ANTIGEN; CD48 ANTIGEN; CD53 ANTIGEN; CHEMOKINE RECEPTOR CXCR3; CHLORDANE; CXCL11 CHEMOKINE; CXCL2 CHEMOKINE; CXCL9 CHEMOKINE; GLUCOCORTICOID INDUCED TUMOR NECROSIS FACTOR RECEPTOR; HLAE PROTEIN; IFI27 PROTEIN; IFNAR1 PROTEIN; INTERFERON CONSENSUS SEQUENCE BINDING PROTEIN; INTERFERON REGULATORY FACTOR 2; INTERFERON REGULATORY FACTOR 5; INTERFERON REGULATORY FACTOR 9; ITK PROTEIN; KLRK1 PROTEIN; LGMN PROTEIN; PROTEIN; PROTEIN KINASE LCK; RANTES; STAT1 PROTEIN; TOLL LIKE RECEPTOR 7; TRANSCRIPTION FACTOR GATA 3; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER EPIDEMIOLOGY; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CUTANEOUS MELANOMA; DISEASE COURSE; DISEASE SPECIFIC SURVIVAL; FEMALE; FOLLOW UP; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE REGULATORY NETWORK; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MITOSIS RATE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENCE FREE SURVIVAL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR LOCALIZATION;

ANTIGENS, CD2; BAYES THEOREM; GENE REGULATORY NETWORKS; GENES, P53; HUMANS; MELANOMA; NEOPLASM STAGING;

EID: 84904462098     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2014.85     Document Type: Article

References (23)

1. Ascierto PA, Capone M, Urba WJ et al. (2013) The additional facet of immunoscore: Immunoprofiling as a possible predictive tool for cancer treatment. J Transl Med 11:54
2. Azimi F, Scolyer RA, Rumcheva P et al. (2012) Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma. J Clin Oncol 30:2678-83
3. Balch CM, Gershenwald JE, Soong SJ et al. (2009) Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27:6199-206
4. Balch CM, Gershenwald JE, Soong SJ et al. (2010) Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: Comparison of nodal micrometastases versus macrometastases. J Clin Oncol 28:2452-9
5. Balch CM, Soong SJ, Gershenwald JE et al. (2001) Prognostic factors analysis of 17,600 melanoma patients: Validation of the American Joint Committee on cancer melanoma staging system. J Clin Oncol 19:3622-34
6. Bindea G, Mlecnik B, Fridman WH et al. (2011) The prognostic impact of anticancer immune response: A novel classification of cancer patients. Semin Immunopathol 33:335-40
7. Bogunovic D, O'Neill DW, Belitskaya-Levy I et al. (2009) Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival. Proc Natl Acad Sci USA 106:20429-34
8. Busam KJ, Antonescu CR, Marghoob AA et al. (2001) Histologic classification of tumor-infiltrating lymphocytes in primary cutaneous malignant melanoma. A study of interobserver agreement. Am J Clin Pathol 115:856-60
9. Clemente CG, Mihm MC Jr, Bufalino R et al. (1996) Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 77:1303-10
10. Fortina P, Surrey S (2008) Digital mRNA profiling. Nat Biotechnol 26:293-4
11. Francken AB, Accortt NA, Shaw HM et al. (2008) Prognosis and determinants of outcome following locoregional or distant recurrence in patients with cutaneous melanoma. Ann Surg Oncol 15:1476-84
12. Fridman WH, Galon J, Dieu-Nosjean MC et al. (2011) Immune infiltration in human cancer: Prognostic significance and disease control. Curr Top Microbiol Immunol 344:1-24
13. Galon J, Angell HK, Bedognetti D et al. (2013) The continuum of cancer immunosurveillance: Prognostic, predictive, and mechanistic signatures. Immunity 39:11-26
14. Geiss GK, Bumgarner RE, Birditt B et al. (2008) Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat Biotechnol 26:317-25
15. Harbst K, Staaf J, Lauss M et al. (2012) Molecular profiling reveals lowand high-grade forms of primary melanoma. Clin Cancer Res 18: 4026-36
16. Kruit WH, Suciu S, Dreno B et al. (2013) Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: Results of a randomized phase II study of the European Organisation for research and treatment of cancer melanoma group in metastatic melanoma. J Clin Oncol 31: 2413-20
17. Loetscher P, Uguccioni M, Bordoli L et al. (1998) CCR5 is characteristic of Th1 lymphocytes. Nature 391:344-5
18. Mann GJ, Pupo GM, Campain AE et al. (2013) BRAF mutation, NRAS mutation, and the absence of an immune-related expressed gene profile predict poor outcome in patients with stage III melanoma. J Invest Dermatol 133:509-17
19. Manolio TA, Chisholm RL, Ozenberger B et al. (2013) Implementing genomic medicine in the clinic: The future is here. Genet Med 15:258-67
20. Morton DL, Thompson JF, Cochran AJ et al. (2006) Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med 355:1307-17
21. Ott PA, Carvajal RD, Pandit-Taskar N et al. (2013) Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma. Invest New Drugs 31:425-34
22. Winnepenninckx V, Lazar V, Michiels S et al. (2006) Gene expression profiling of primary cutaneous melanoma and clinical outcome. J Natl Cancer Inst 98:472-82
23. Wong SL, Balch CM, Hurley P et al. (2012) Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline. J Clin Oncol 30:2912-8